252 related articles for article (PubMed ID: 27065708)
1. Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer.
Bhatt A; Goéré D
Indian J Surg Oncol; 2016 Jun; 7(2):177-87. PubMed ID: 27065708
[TBL] [Abstract][Full Text] [Related]
2. Management of colorectal cancer patients at high risk of peritoneal metastases.
Shariff U; Seretis C; Youssef H
J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
[TBL] [Abstract][Full Text] [Related]
3. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
[TBL] [Abstract][Full Text] [Related]
4. Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis.
Gao Z; Qi X; Wang R; Wen Z; Qi H; Ju M; Liu X; Wang J; Zhou H; Zhu Z; Liu X; Li K
Eur J Surg Oncol; 2024 Jun; 50(9):108474. PubMed ID: 38870874
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.
de Cuba EM; Kwakman R; Knol DL; Bonjer HJ; Meijer GA; Te Velde EA
Cancer Treat Rev; 2013 Jun; 39(4):321-7. PubMed ID: 23244778
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases from Colorectal Cancer-An Overview of Current Status and Future Perspectives.
Graf W; Ghanipour L; Birgisson H; Cashin PH
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254775
[TBL] [Abstract][Full Text] [Related]
7. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Summary of Key Clinical Trials.
Turner KM; Morris MC; Sohal D; Sussman JJ; Wilson GC; Ahmad SA; Patel SH
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743476
[TBL] [Abstract][Full Text] [Related]
9. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.
Vassos N; Piso P
Curr Treat Options Oncol; 2018 Sep; 19(10):49. PubMed ID: 30173342
[TBL] [Abstract][Full Text] [Related]
11. Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review.
Beal EW; Suarez-Kelly LP; Kimbrough CW; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Lee B; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Powers B; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Russell MC; Zaidi MY; Patel SH; Dhar V; Lambert L; Hendrix RJ; Hays J; Abdel-Misih S; Cloyd JM
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32164300
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review.
Eveno C; Pocard M
Pleura Peritoneum; 2016 Dec; 1(4):169-182. PubMed ID: 30911621
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.
Mertens LS; Behrendt MA; Mehta AM; Stokkel L; de Jong J; Boot H; Horenblas S; van der Heijden MS; Moonen LM; Aalbers AGJ; Meinhardt W; van Rhijn BWG
Eur J Surg Oncol; 2019 Sep; 45(9):1740-1744. PubMed ID: 31003721
[TBL] [Abstract][Full Text] [Related]
14. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.
Steffen T; Putora PM; Hübner M; Gloor B; Lehmann K; Kettelhack C; Adamina M; Peterli R; Schmidt J; Ris F; Glatzer M
Clin Colorectal Cancer; 2019 Dec; 18(4):e335-e342. PubMed ID: 31371166
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases.
Baratti D; Kusamura S; Iusco D; Gimondi S; Pietrantonio F; Milione M; Guaglio M; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
Ann Surg Oncol; 2017 Jan; 24(1):167-175. PubMed ID: 27519353
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
[TBL] [Abstract][Full Text] [Related]
18. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
19. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer.
Simkens GA; Rovers KP; Nienhuijs SW; de Hingh IH
Cancer Manag Res; 2017; 9():259-266. PubMed ID: 28721098
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
